Sanofi and Rockefeller University to develop Alzheimer's treatment
French drugmaker Sanofi-aventis has entered a global licensing agreement with The Rockefeller University in New York concerning a novel monoclonal antibody for the treatment of Alzheimer\'s disease.
French drugmaker Sanofi-aventis has entered a global licensing agreement with The Rockefeller University in New York concerning a novel monoclonal antibody for the treatment of Alzheimer's disease.
This antibody therapy targets certain forms of the Amyloid Beta parenchymal plaque, which may lead to cognitive improvement in Alzheimer's patients. It will start development at the end of this year.
According to Jeffrey Ravetch, head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at The Rockefeller University, initial studies have suggested that this antibody may be an effective way of reducing the progression of Alzheimer's disease.
Ravetch discovered the original murine monoclonal antibody targeting the Amyloid Beta peptide.
Under the terms of the agreement, Sanofi-aventis will develop, manufacture and commercialise the anti-ABeta antibody. Financial terms were not disclosed.